Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389696 | 0.89 | GPR119 (0.48) | GPR119FAAHKEAP1NFE2L2KDM4E | |
| SCHEMBL389697 | 0.89 | GPR119 (0.48) | GPR119FAAHKEAP1NFE2L2KDM4E | |
| SCHEMBL10102356 | 0.87 | GPR119 (0.61) | GPR119USP30KEAP1NFE2L2NAMPT | |
| SCHEMBL16480368 | 0.86 | TP53 (0.41) | GPR119FAAHKDM4EPKM | |
| SCHEMBL2407707 | 0.85 | PDE4B (0.43) | USP30 | |
| SCHEMBL2407705 | 0.85 | PDE4B (0.43) | USP30 | |
| SCHEMBL391289 | 0.83 | GPR119 (0.48) | GPR119USP30KDM4ENAMPT | |
| SCHEMBL391290 | 0.83 | GPR119 (0.48) | GPR119USP30KDM4ENAMPT | |
| SCHEMBL390097 | 0.78 | GPR119 (0.49) | GPR119FAAHKEAP1NFE2L2KDM4E | |
| SCHEMBL390096 | 0.78 | GPR119 (0.49) | GPR119FAAHKEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | GPR119, GCGR, GLP1R | GPR119 1/4885USP30 4323/4885FAAH 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.